Inherited optic neuropathies include complex phenotypes, mostly driven by mitochondrial dysfunction. We report an optic atrophy spectrum disorder, including retinal macular dystrophy and kidney insufficiency leading to transplantation, associated with mitochondrial DNA (mtDNA) depletion without accumulation of multiple deletions. By whole-exome sequencing, we identified mutations affecting the mitochondrial single-strand binding protein (SSBP1) in 4 families with dominant and 1 with recessive inheritance. We show that SSBP1 mutations in patient-derived fibroblasts variably affect the amount of SSBP1 protein and alter multimer formation, but not the binding to ssDNA. SSBP1 mutations impaired mtDNA, nucleoids, and 7S-DNA amounts as well as mtDNA replication, affecting replisome machinery. The variable mtDNA depletion in cells was reflected in severity of mitochondrial dysfunction, including respiratory efficiency, OXPHOS subunits, and complex amount and assembly. mtDNA depletion and cytochrome c oxidase-negative cells were found ex vivo in biopsies of affected tissues, such as kidney and skeletal muscle. Reduced efficiency of mtDNA replication was also reproduced in vitro, confirming the pathogenic mechanism. Furthermore, ssbp1 suppression in zebrafish induced signs of nephropathy and reduced optic nerve size, the latter phenotype complemented by WT mRNA but not by SSBP1 mutant transcripts. This previously unrecognized disease of mtDNA maintenance implicates SSBP1 mutations as a cause of human pathology. SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder
Introduction
The expanding genetic landscape of inherited optic neuropathies has highlighted mitochondrial dysfunction as a major driver of this pathology (1, 2) . Overall, the genetic defects leading to optic atrophy range from mitochondrial DNA (mtDNA) point muta tions in Leber hereditary optic neuropathy (LHON) (3) to domi nant and recessive mutations affecting a cluster of nuclear genes implicated in mitochondrial dynamics (4) . These include OPA1, whose protein product is necessary for fusing the inner mitochon
Results
Exome sequencing identifies dominant and recessive mutations in SSBP1 SSBP1 mutations and their segregation in 5 unrelated families. Two unrelated families from Italy and the US with the common feature of congenital or early onset optic atrophy, negative for the most frequent causes, underwent trio whole exome sequencing (WES) independently in different centers (Supplemental Methods and Supplemental Table 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI128514DS1).
De novo mutations in SSBP1 were identified in both families, which we connected through GeneMatcher (22) . In the Italian family (family 1 in Figure 1 ), we identified a heterozygous mis sense mutation NM 003143.2: c.320G>A (p.R107Q) (Supplemen tal Table 2 ), which arose de novo in the father and was transmitted to his affected child. The US proband (family 2 in Figure 1 ) carried a de novo heterozygous missense mutation, c.119G>T (p.G40V) (Supplemental Table 2 ).
Based on these findings, a total of 135 Italian probands with optic atrophy of unknown genetic origin were screened for SSBP1 mutations. In 2 unrelated individuals, we found additional hetero zygous missense mutations in SSBP1: c.331G>C (p.E111Q) in family 3 and c.184A>G (p.N62D) in family 4 ( Figure 1 and Supple mental Table 2) . No members of family 3 were available for segre gation. In family 4, the heterozygous mutation segregated in both proband's offspring, whereas it was absent in his mother (the only parent available for testing). The father died in his 70s, without any report of visual impairment. The segregation was therefore compatible with a de novo event in the proband.
In a fifth family from Austria with a single proband (family 5 in Figure 1 ) presenting with a largely overlapping phenotype, WES identified a homozygous mutation in SSBP1, c.394A>G (p.I132V) (Supplemental Table 2 ). Parental consanguinity was not report ed, and estimation of genomic inbreeding using WES data failed to reveal excess of homozygosity (Supplemental Table 3 ). Homo zygosity for p.I132V can be explained as a founder mutation because the parents were from a remote mountain area in Austria.
Clinical presentation of affected individuals. Family 1 included 2 probands, a father and son, who presented with childhood onset optic atrophy, retinal macular dystrophy, sensorineural deafness, and nephropathy, which in the child ultimately led to kidney transplantation (Figure 2 , A-C, Supplemental Figure 1 , drial membrane (5, 6) , MFN2, for fusion of the outer mitochon drial membrane (7) , DNM1l (8) , OPA3 (9) , and SLC25A46 (10), involved in mitochondrial fission. In addition to optic neuropathy, mutations in several of these genes have also been hallmarked by broader clinical phenotypes defined as "plus," associated with mtDNA instability, as characterized by secondary accumulation of multiple deletions in postmitotic tissues, such as skeletal mus cle and brain (11) (12) (13) . In patients, mtDNA multiple deletions are phenotypically reflected by ocular myopathy with chronic pro gressive external ophthalmoplegia (CPEO) and ptosis, in associ ation or not with more widespread brain involvement, including parkinsonism and dementia (14, 15) .
Originally, CPEO and ptosis with mtDNA multiple deletions were noted for their remarkable association of Mendelian inheri tance and secondary mtDNA instability (16) . The genes associated with this initial group of mitochondrial disorders were all implicated in mitochondrial replisome, such as the mitochondrial polymerase (POLG1 and POLG2), the helicase Twinkle (TWNK), other genes instrumental to mtDNA replication (RRM2B, RNaseH1, DNA2, MGME1), and genes implicated in nucleotide availability and bal ance (SLC25A4, TYMP, TK2, DGOUK, MPV17) (17) .
We are now aware that allelic mutations in all these genes, respectively implicated in mitochondrial dynamics, replisome, and nucleotide metabolism, may either affect so profoundly mtDNA replication that the major outcome is depletion of mito genomes with fatal infantile encephalomyopathies or induce slow somatic accumulation of mtDNA multiple deletions with various syndromes of adult life dominated by CPEO (18) .
However, one key factor implicated in mtDNA replication has been missing: mitochondrial singlestrand binding protein 1 (SSBP1), whose cDNA cloned in 1993 (19) and whose gene was mapped to 7q34 in 1995 (20) . Despite being a good candidate for mtDNA main tenance disorders, it was not pathogenically associated with any human disease. SSBP1 has been shown to coat the displaced, parental Hstrand during mtDNA synthesis, a critical function according to the strand displacement mode of mtDNA replication (21) .
Here, we report the identification of a spectrum of phenotypes associated with SSBP1 mutations and mtDNA depletion transmit ted as autosomal dominant and recessive traits that ranged from isolated optic atrophy to additional clinical features, including retinal macular dystrophy, sensorineural deafness, mitochondrial myopathy, and kidney failure necessitating transplantation. revealed a copy number in the lower end of the control range, sug gesting a tendency to reduction (Supplemental Figure 2J ).
The proband of family 5, with homozygous p.I132V, initially developed blindness due to retinal dystrophy and deafness. This clinical picture was later complicated by hypertrophic cardio myopathy, nephropathy, ataxia,and growth retardation. Muscle biopsy revealed COXnegative fibers; biochemical studies doc umented a combined deficiency of complexes I and III, whereas citrate synthase (CS) was elevated.
SSBP1 mutations frequency and in silico prediction of deleteriousness. All dominant mutations were novel based on the vari ant database gnomAD, version 2.0.2. The recessive mutation was reported in only 2 heterozygous alleles in gnomAD and was absent in the homozygous state. All missense mutations were evolutionarily conserved (phyloP100way scores ranging 6.2 to 8.9), with high potential for deleteriousness according to Com bined Annotation Dependent Depletion (CADD Phred scores ranging from 21.8 to 29.4) (Supplemental Table 2 ). All mutations mapped within the singlestrand binding domain ( Figure 4A ), and 2 of them (p.R107Q and p.E111Q) affected residues under the strongest purifying selection relative to SSBP1 according to missense tolerance ratio (MTR), having MTRs within the fifth percentile of most missense depleted regions of the gene (Fig  ure 4B ). Mutations p.G40V, p.R107Q, and p.E111Q are predicted to disrupt molecular function according to in silico protein structure modeling by VIPUR (https://github.com/EvanBaugh/ VIPUR) (Supplemental Methods, Supplemental Table 4 , and ref. 23 ), although with seemingly distinct deleterious effects ( Figure  4C ). The p.G40V is predicted to have an unfavorable backbone conformation and appears to disrupt the interaction of SSBP1 with ssDNA by destabilizing the nearby nucleotidebinding res idues. Conversely, p.E111Q and p.R107Q are predicted to affect SSBP1 oligomerization by disruption of stabilizing salt bridges of E111 and R107 with H34 and E27, respectively. Both p.N62D and p.I132V are not predicted to be grossly disruptive. However, p.N62D occurs at dimer interface and in close spatial proximity to R107 and introduces a negative charge that may interfere with dimerization. Finally, p.I132V is assumed to be tolerated mainly due to incomplete site conservation; however, it still has a high structural disruption score that suggests destabilizing potential. Notably, all 3 mutations with a disruptive prediction appear to act through distinct mechanisms: p.G40V damaging ssDNA binding, p.R111Q disrupting tetramer assembly, and p.R107Q disrupting both dimerization and tetramerization.
Analysis of SSBP1 in patient-derived mutant fibroblasts
To assess the functional impact of SSBP1 mutations on protein levels, we performed Western blot analysis on mitochondria iso lated from primary fibroblasts of 4 patients (both patients from family 1, probands from families 2 and 5) and from controls. Quantification of SSBP1 relative to the loading control VDAC1 indicated that abundance of p.R107Q mutant was comparable to that of controls, while p.G40V showed a significantly increased level of about 25% and p.I132V mutant a significant decrease of 39 % protein level instead ( Figure 5 , A and B). Immunofluo rescence experiments evaluating colocalization of SSBP1 with MitoTracker red revealed a trend, congruent with Western blot and Supplemental Methods). Muscle and kidney biopsies from both patients revealed histoenzymatic features compatible with mitochondrial dysfunction, such as cytochrome c oxidasenegative (COXnegative) cells ( Figure 2 , B and C, and Supple mental Figure 1B ). The mtDNA molecular analysis revealed partial depletion of copy number in both tissues ( Figure 2 , D and E). Bloodderived cells were also mtDNA depleted, similarly to kidney and muscle ( Figure 2F ). However, both long range and digital droplet PCR failed to identify and quantify mtDNA deleted molecules in kidney, muscle, blood, and urinary sed iment cells (Supplemental Figure 2 , A-D). A slight reduction of 7S DNA, the third strand of the mtDNA displacement loop (Dloop) was also noted (Supplemental Figure 2 , E-H). Thus, muscle and kidney histoenzymatic analysis, as well as mtDNA investigations, were suggestive of mitochondrial dysfunction as pathogenic mechanism.
Family 2 included a single proband presenting a similar pheno type, with childhoodonset severe optic atrophy and progressive retinal degeneration exhibiting a conerod dystrophy (CORD) phenotype (Figure 3 ). Despite relatively good foveal preservation, visual acuity was severely reduced due to the severity of the optic atrophy. In association with these eye findings, this patient also exhibited progressive nephropathy requiring transplantation and sensorineural hearing loss. No functional or histological studies were available for this patient.
The sporadic patient of family 3 was in his 70s and presented with isolated optic atrophy and no retinal changes in the macula. The proband of family 4 had 2 affected offspring with neuro ophthalmological assessment revealing features virtually identical to those of family 1 in all 3 individuals ( Figure 2A ). The mtDNA analysis in bloodderived cells of patients from families 3 and 4 with isolated mitochondria treated with 0.1% glutaraldehyde (GA) to induce protein crosslinking or left untreated. Lysates were then separated on a denaturing SDSpolyacrylamide gel and the SSBP1 monomer, dimer, trimer, and multimer were analysis, toward an increase in the mutant p.G40V protein and decrease in the p.I132V ( Figure 5 , C and D).
To monitor the effects of the mutations on homooligomeri zation of SSBP1, we performed a protein crosslinking experiment Middle inset: Arg107 occurs on the outer surface of the homotetramer at both homodimeric and homotetrameric interfaces. It is spatially close to Glu27 (5.3°A away) and likely forms a stabilizing salt -bridge across the dimer interface. Lower inset: Glu111 occurs directly in the tetrameric interface and potentially forms a stabilizing salt bridge with His34, although the available model does not clearly indicate the monomer this interaction occurs with (both His34 residues on opposing dimers are spatially close to Glu111, 7.7°A and 8.7°A, respectively). Figure 3A) . However, as observed by differential scanning fluorimetry, the p.I132V mutation has a somewhat lower thermostability than WT SSBP1, indicative of mild alterations to the physical properties of the mutation, though both proteins melt well above physiologically relevant temperatures (Supplemental Figure 3B ). Together, these experiments suggest that the different mutations did not prevent binding of SSBP1 to ssDNA under these experimental conditions.
Analysis of mutant fibroblasts reveals depletion of mtDNA and nucleoids with altered dynamics of mitogenomes repopulation and impaired in vitro replication Based on the partial mtDNA depletion observed in patient derived tissues (Figure 2 , D-F), we investigated mtDNA mainte nance in SSBP1 mutant fibroblasts by quantifying nucleoid and mtDNA copy numbers compared with those of controls. In all 4 patient cell lines, we found significantly reduced mtDNA content, ranging from 54% to 78% depletion compared with that of con trols ( Figure 6A ). The p.I132V mutation appeared the less severe in terms of mtDNA depletion, whereas p.R107Q II and p.G40V were the most severe ( Figure 6A ). This result was matched by nucle oid quantification, as assessed by PicoGreen/MitoTracker red combined staining, showing a significant reduction of nucleoids, which were particularly prominent in p.R107Q II and p.G40V cells ( Figure 6 , B and C).
To assess the global efficiency of mtDNA replication, we next performed a depletion/repopulation experiment, in which cells were mtDNA depleted by 7 days of exposure to low concen trations of ethidium bromide (EtBr), followed by its withdrawal and mtDNA repopulation in 15 days. Each mutant cell line started from a lower mtDNA content at point 0, reached a pro found depletion similar to that of controls at day 7, and resumed mtDNA replication with different efficiencies ( Figure 6D ). The most severe effects were observed for p.R107Q and p.G40V mutations, whereas the homozygous p.I132V mutation was associated with milder outcomes. Considering the mtDNA amount at point 0 as 100 %, it is notable that only p.R107Q was significantly slower in mitogenomes repopulation (Supplemen tal Figure 4A ). At the last time point of this experiment, all cell lines regained approximately the original levels of mtDNA copy number, with the exception of R107Q I.
The same samples were also quantified for 7S DNA ( Figure  6E ). Control fibroblasts at time 0 had ratio of 7S DNA/mtDNA of approximately 0.43. This ratio matched perfectly the changes of mtDNA copy number during the EtBr experiment in controls, with a similar pattern for the mild p.I132V mutation (ratio 0.28 at time 0). In contrast, p.R107Q and p.G40V mutations showed a low amount of 7S DNA (0.09 and 0.03 at time 0, respectively), which remained mostly unchanged during the experiment. No deletions were observed at times 0 and 15 (data not shown).
To assess the possible presence of low levels of mtDNA het eroplasmic mutations, which might expand after the depletion/ repopulation experiment, mtDNA deep sequencing (mean cover age 7412X) was carried out at point 0 and at 15 days after EtBr with drawal. Overall, mutant cells at time 0 had a significantly higher number of heteroplasmic variants, considering heteroplasmy detected by Western blot. In the absence of GA (-) the majority of SSBP1 was in the monomeric form (molecular weight of approx imately 15 kDa), whereas in the presence of GA (+), some SSBP1 oligomers were crosslinked ( Figure 5E ). The relative levels of the oligomeric crosslinked products (GA+) and the monomeric form (GA-) were determined by densitometry and expressed as a ratio, where the ratio for controls was set equal to 1 ( Figure 5F ). The p.R107Q and p.G40V mutations induced the accumulation of dimeric and trimeric forms, while the detection of SSBP1 tetram ers and multimers was severely reduced in the case of p.R107Q, but not affected by p.G40V. In the cell line with p.I132V muta tion, we hardly detected any trimeric and multimeric products. These results suggest that p.R107Q and p.I132V mutations inter fere with SSBP1 multimerization.
Next, we tested binding of WT and affected proteins to ssDNA. We performed an in vitro pulldown assay by incubating mito chondrial lysate with biotinylated ssDNA. We found that the SSBP1 antibody detected the protein only in the pulldown fraction both in controls and patients ( Figure 5G ). No protein was observed in the supernatant, indicating that WT and SSBP1 mutants were able to bind ssDNA. Moreover, antiHSP60, anti VDAC, and antiETHE1 antibodies were able to detect the cor responding proteins exclusively in the supernatant, but not in the pulldown fraction. These results indicated that only the SSBP1ssDNA complex was precipitated specifically. Since we were wondering how the complex SSBP1(p.I132V muta tion)ssDNA could be precipitated despite only small amounts of tetramers being detected, we expressed the mutant protein in E. coli and tested its ability to form tetramers. Size exclusion Figure 3A .
(F) Densitometric analysis of E shows that p.R107Q and p.I132V mutations, but not p.G40V, interfere with SSBP1 multimerization. All values represent the ratio between each oligomer amount in the presence of GA and monomers without GA. (G) SSBP1-ssDNA binding assay performed on isolated mitochondria shows that SSBP1 mutants were able to bind ssDNA. Streptavidin-agarose beads were used to precipitate biotinylated ssDNA together with associated proteins. Supernatants and pull-down fractions were run on a SDS-PAGE and immunoblotted with anti-SSBP1, anti-VDAC1, anti-HSP60, and anti-ETHE1 antibodies. A representative blot out of 3 is shown. *P < 0.05; ***P < 0.001. Statistical significance was determined using 1-way ANOVA with Tukey's correction. saturating amounts of SSBP1 that could cover the singlestranded template completely (1 SSBP1 tetramer was calculated to bind 60 nt ssDNA). All mutations were able to support fulllength DNA synthesis ( Figure 7B , compare lanes 1-5, no SSBP1 added, with , but were all less efficient than the WT protein ( Figure  7B , lanes 6-10). In conclusion, all SSBP1 mutations had reduced ability to stimulate POLγdependent DNA synthesis in vitro.
mtDNA depletion reflects on bioenergetics of SSBP1 mutant fibroblasts Considering the mtDNA depletion in all patient fibroblasts, we next characterized the impact of SSBP1 mutations on bioenergetics.
Oxygen consumption rate (OCR) analysis showed a severe respi ratory deficit in both p.R107Q mutant cells and a partial defect in p.G40V, whereas no differences were found for p.I132V mutation ( Figure 8, A and B ). Furthermore, all mutants, with the exception of p.I132V, showed a significant shift toward glycolysis, as indicated by decreased OCR/ECAR ratios (Supplemental Figure 4F ). We also performed Western blot analysis of representative subunits of OXPHOS complexes (Figure 8 , C and D). A marked decrease in the amount of NDUFB8 and NDUFA9 (CI), and COX II (CIV) characterized p.R107Q cells, with a slight reduc tion of UQCRC2 (CIII), which was statistically significant only in R107Q-II. The p.G40V mutation was associated with a milder but significant reduction of CI subunits and an increase of UQCRC2. Concordant with OCR results, p.I132V cells did not show reduction of OXPHOS subunits, but rather an increase of UQCRC2 and COX II. To confirm these data, we quantified the amount of assembled complexes by BlueNative PAGE ( Figure  8E ). All patient cell lines, with the exception of p.I132V, exhibited a significant reduction of CI, both by Western blot and ingel activity ( Figure 8F) , and a partially disassembled complex V (CV), as shown by the appearance of 2 bands at lower molecular weight corresponding to free F1 ( Figure 8G ). No alteration of CIII amounts was observed ( Figure 8F ). Finally, the analysis of super complexes assembly showed similar results, with reduction of supercomplexes containing complex I (I + III 2 , I + III 2 + IV, and I + III 2 + IV n ) and increase of isolated CIII 2 , not assembled with CI, in fibroblasts carrying p.R107Q and p.G40V mutations. Again, the incomplete assembly of CV was detected in these 3 cell lines (Supplemental Figure 4G) .
To assess whether mtDNA depletion was paralleled by a reduction of mitochondrial mass, we quantified CS, TIM23, and TOM20 levels (Figure 8, H and I) . This analysis revealed a slight reduction and an increase of mitochondrial mass in R107Q-II and G40V mutations, respectively.
These results indicate that the SSBP mutations p.R107Q and p.G40V cause an energetic defect driven by CI reduction, a defect that was less severe in the latter mutation, probably due to the compensatory increment of mitochondrial mass. In contrast, fibroblasts carrying p.I132V, despite having mtDNA depletion, did not display a detectable energetic defect.
To evaluate whether the phenotypic defect due to the homo zygous recessive mutation could be rescued by the WT protein, we integrated by lentiviral transduction the WT SSBP1 in a control and in the p.I132V cell lines. The SSBP1 complementation, con firmed by Western blot (Supplemental Figure 5, A and B) , rescued within 20% of total copy number, but the load of heteroplasmy did not differ compared with that of controls and was not substantially changed by the bottleneck due to EtBr treatment at day 15 (Supple mental Figure 4 , B-E). The mtDNA complete sequence of all cell lines and blood circulating cells for the remaining cases allowed for reconstruction of the haplotype of each individual enrolled in this study and their phylogenetic relationship (Supplemental Data File). The only notable variant was observed in the case R107Q II (Pt 2 in family 1), who presented a C insertion at position 57 (57insC) within the OH region that we believe to be novel.
Next, we quantified the levels of TFAM and other components of the mtDNA replisome ( Figure 6 , F and G). Western blot analysis revealed a significant reduction of TFAM, RNaseH1, and TWIN KLE in both p.R107Q mutant cells, with only a modest decrease of POLγ. In contrast, we did not observe any protein reduction in the other 2 mutant cell lines, with a significant increase of POLγ in p.G40V mutant. Overall, these results suggest a severe effect of p.R107Q and p.G40V mutations on mtDNA maintenance, repli cation, and 7S DNA amounts in fibroblasts. The p.I132V mutation was associated with only a baseline mtDNA reduction, confirming its milder nature.
SSBP1 is known to stimulate the activity of POLγ (24); thus, we decided to investigate in vitro whether the identified mutations affected this ability. To this end, we purified WT SSBP1 and mutant derivatives thereof in recombinant form and analyzed them using SDS-PAGE to confirm purity ( Figure 7A ). We next monitored the ability of SSBP1 to stimulate DNA synthesis on a circular, ssDNA template of about 3000 nt in the presence of POLγ. The primer needed to initiate DNA synthesis was a 32 Plabeled oligonucle otide (50 nt) that had been annealed to ssDNA substrate. We used and F). Additionally, we performed quantitative reversetranscrip tase PCR (qRT-PCR) on RNA harvested from F0 ssbp1 embryos at 2 dpf (Supplemental Figure 6G ), but consistent with our optic nerve phenotyping data, we did not find any significant differences between mutants and controls. We hypothesized that the apparent lack of early optic nerve phenotype in F0 mutants could be due to the presence of mater nal ssbp1, and we aged animals for evaluation at later time points. By 3 weeks after fertilization, we saw marked growth restriction and lethality in F0 larvae compared with controls. We speculated that the F0 mutant lethality could be due to the depletion of mito chondria over time. To explore this possibility, we injected 50 pg sgRNA plus 100 pg Cas9 protein into the Tg(XlEef1a1:mlsEGFP) transgenic zebrafish line, which targets GFP to the mitochondria with the COXVIII mitochondrial localization signal (mls). We aged F0 mutants to 15 dpf, obtained lateral fluorescent images, and quantified GFP intensity in the lens of live anesthetized embryos. Consistent with our hypothesis, we found a significant reduction of green signal in F0 mutants compared with controls or larvae injected with sgRNA alone (Supplemental Figure 6 , H and I).
We next sought to evaluate the effects of sspb1 loss at an ear lier developmental time point by using a translation blocking (tb) morpholino (MO) to suppress ssbp1 transcript (both maternal and embryonic mRNA; Supplemental Figure 7A ). To determine the efficiency of ssbp1 tb MO, we performed immunoblotting on total protein extracted from pools of embryos at 2 dpf; we observed depletion of ssbp1 protein in morphants reduced to approximately 5% of protein levels in controls (Supplemental Figure 7 , B and C). Next, we tested a dose curve by injecting tbMO in 1 to 4cell stage embryos at 3 different doses (1 ng, 2 ng, and 3 ng). Immu nostaining and quantification of optic nerve chiasm area at 2 dpf showed a dosedependent and significant reduction in optic nerve size for each dose tested in comparison with controls (Supplemen the mtDNA copy number and induced a nonsignificant increase in respiration in p.I132V cells (Supplemental Figure 5 , C-E).
Disruption of ssbp1 in zebrafish results in optic nerve atrophy and mitochondrial depletion SSBP1 has an established role in mitochondrial biogenesis, and previous RNA in situ hybridization studies have documented ubiq uitous expression in zebrafish from 0 to 2.5 days post fertilization (dpf) (25) . To establish relevance of SSBP1 disruption to the optic atrophy phenotype of patients, we generated zebrafish models. We performed reciprocal BLAST searches and identified a single ortholog in the zebrafish genome (72 % identity; 87 % similarity for human [NP_003134.1] versus zebrafish [NP_001017806.1] protein). Next, we generated and characterized an efficient sgRNAtargeting ssbp1 exon 4 (Supplemental Figure 6A) ; we injected 50 pg sgRNA with 100 pg of Cas9 protein into 1cell stage embryos, performed heteroduplex analysis, and estimated an average mosaicism of approximately 94 % in F0 mutant embryos (Supplemental Figure 6 , B and C). At 2 dpf, F0 ssbp1 mutants dis played no overt morphological abnormalities compared with con trols (Supplemental Figure 6D ).
We and others have reported previously that the zebrafish is a tractable model for evaluating optic nerve ultrastructure (26, 27) . To assess optic nerve integrity, we conducted immunostaining of wholemount F0 mutant embryos fixed at 2 dpf and stained with antiacetylated tubulin antibody (investigator masked to experi mental condition). We acquired ventral images of wholemount embryos using fluorescence microscopy and measured the area of the optic nerve chiasm at a consistent position framed bilaterally by the notochord (Figure 9A and Supplemental Figure 6E ). We found that F0 mutants displayed an optic nerve phenotype indis tinguishable from that of uninjected controls or batches injected with an equivalent dose of sgRNA alone (Supplemental Figure 6 , E 
Discussion
We report SSBP1 mutations associated with an optic atrophy spec trum disorder, including retinal dystrophy, kidney insufficiency requiring transplantation, sensorineural deafness, and mitochon drial myopathy with mtDNA depletion. SSBP1 mutations impaired mtDNA maintenance and replication, as demonstrated in cells and in vitro. Reduced mtDNA copies were reflected in a variable phenotype of impaired OXPHOS, either in vitro in the study of fibroblasts or ex vivo in biopsies of affected tissues, such as kid ney and skeletal muscle. In zebrafish, loss of ssbp1 was shown to affect optic nerve development and induce signs of nephropathy. All mutants failed to rescue the optic nerve phenotype, suggesting that dominant mutations induced loss of function, whereas the recessive behaved as a hypomorph. From the genotypephenotype standpoint, a few features deserve a comment. To date, almost all mtDNAdepletion disor ders are fatal infantile syndromes (17), whereas we describe an adult disease dominated by optic atrophy with pure partial mtDNA depletion, without coexisting multiple deletions. A further example of adult phenotype with prevalent mtDNA depletion is the spectrum disorder associated with recessive mutations in MPV17, ranging from severe epathocerebral encephalopathy to adult neurohep athopathy, recurrent in Navajo Indians (31, 32) . In contrast, mitochondrial neurogastrointestinalencephalopathy (MNGIE), another adult disease with mtDNA depletion, also combines mul tiple deletions and CPEO/ptosis (33) . Remarkably, none of our patients displayed CPEO or ptosis, which is usually the hallmark of mtDNA multiple deletion accumulation, such as in MNGIE and DOA "plus" phenotypes (11, 12, 14, 15, 17) , or of sporadic mtDNA single deletion, such as in KearnsSayre syndrome (KSS) (34) . Thus, these SSBP1 mutations selectively impinge on efficiency of mtDNA replication, apparently without affecting its fidelity. Interestingly, optic atrophy most probably is a congenital or child hoodonset reduction of axons that remains stable in adulthood, frequently combined with a prevailing cone retinal degenera tive phenotype that worsens over time. Most patients exhibited a foveal cone photoreceptor ellipsoid zone (EZ) loss, visible as a foveal hyporeflective gap of EZ and retinal pigmented epithelium (RPE) layers (Figure 2A) . This resembles the known cavitation lesions seen in congenital disorders, such as achromatopsia (35, 36) and blue cone monochromacy (37) , as well as in degenera tive entities, such as KCNV2related retinopathy (38) . A progres sive conepredominant disease expression configuring a CORD pheno type was seen in the family 2 (p.G40V) proband, lacking the foveal cavitation, but with a unique hyperreflectivity that also persisted as the retinal disease progressed. These neuroretinal features have not been previously reported in mtDNA depletion syndromes, although a CORD phenotype was found in KSS (34), whereas kidney involvement was observed since the first study on infantile syndromes with mtDNA depletion (39) . Besides the genotypephenotype variability with different SSBP1 mutations, a different severity was also observed within family 1 (p.R107Q). Dominant disorders frequently display incomplete penetrance, tal Figure 7 , D and E). To determine the specificity of the tbMO phenotype, we coinjected WT human SSBP1 mRNA with MO and observed a significant amelioration of the optic nerve phenotype to a level nearly indistinguishable from that of controls ( Figure  9 , A-C, and Supplemental Figure 8, A and B) . We also matured larvae to 4 dpf, a developmental time point by which the zebra fish pronephros is formed (28, 29) . We noted a dosedependent cardiac, yolk sac, and periorbital edema suggestive of nephrop athy (ref. 30 and Supplemental Figure 7 , F and G). However, oth er phenotypes, such as abnormal otolith formation (a proxy for the mammalian ear), relevant to our SSBP1 human cohort were indistinguishable in ssbp1 morphants versus controls (Supple mental Figure 9A ). Additionally, we did not detect differences in mlsEGFP quantity in morphants on our mitochondrial transgenic reporter at 2 dpf, possibly due to detection thresholds at this early developmental stage (Supplemental Figure 9, A and B) . Final ly, we quantified mtDNA content in ssbp1 morphants and con trols using a quantitative PCR (qPCR) assay to monitor mtDNA amount relative to nuclear DNA (nDNA) (using mt-nd1 and polg1 primers, respectively; 2 dpf embryo pools of 30 embryos each) and did not detect significant differences between either exper imental group (Supplemental Figure 9C) .
In vivo complementation is a sensitive and specific approach for testing pathogenicity of nonsynonymous mutations in the context of optic nerve phenotypes (26) . To test the effect of the missense mutations identified in affected individuals (includ ing those studied in fibroblasts as well as the other 2 mutations found in families 3 and 4), we coinjected MO with SSBP1 muta tionbearing mRNAs and compared their rescue efficiency with that of WT SSBP1 message or MO alone. For each of the p.G40V, p.N62D, p.R107Q, p.E111Q, and p.I132V encoding mRNAs, we detected no significant differences between MO alone and mutant mRNA rescue experiments, suggesting that they are functional null mutations (Figure 9 , A-C, and Supplemental Fig  ure 8, A and B) . Consistent with the in vitro studies, we observed a milder effect for p.I132V, the sole mutation that segregated in a recessive inheritance pattern. Although p.I132V mRNA rescued optic nerve chiasm area less efficiently than WT mRNA, the mean optic nerve area was improved by 18% in p.I132V rescue batches compared with MO alone (P = 0.0148, 2tailed unpaired t test). However, this difference did not reach statistical signif icance when corrected for multiple testing (Figure 9 , A-C, and Supplemental Figure 8, A and B) . Further, SSBP1 complementa tion with mRNA harboring a common variant (p.L75P: 5 homo zygotes in gnomAD; MAF 1.776e3) rescued similarly to WT mRNA, supporting the specificity of our assay (Figure 9 , A-C, and Supplemental Figure 8, A and B) . Injection of mRNA encod ing any of the 5 patients' mutations, p.L75P, or WT SSBP1 yielded no apparent optic nerve phenotype compared with controls ( Fig  ure 9D and Supplemental Figure 8C ). Moreover, titration of WT and p.R107Q mRNAs did not show any significant phenotype (Supplemental Figure 8D ), suggesting that dominantnegative effect of these mutations is unlikely.
Together, our data indicate that MObased zebrafish models of ssbp1 suppression recapitulate optic nerve atrophy observed in individuals with dominant and recessive SSBP1 mutations. Fur thermore, our in vivo complementation data suggest that missense possibly giving a molecular explanation of the disease phenotype, i.e., decreasing POLγ activity.
Notably, all patients' mutations were missense changes, while we found no proteintruncating or splicesite alterations. This suggests that SSBP1 dosage reduction is not the molecular mecha nism underlying disease. Consistently, we did not observe reduc tion in protein products by Western blot, except for the recessive p.I132V. In large public population databases such as gnomAD, a few ultrarare potential dosageaffecting SSBP1 alleles (Supple mental Table 5 ) suggest that monoallelic haploinsufficiency may be tolerated or be implicated in overlapping disease phenotypes as possibly hypomorphic alleles. An example of this is the startloss c.3G>A variant proposed to act as modifier for penetrance of the m.1555A>G mtDNA deafness mutation, associated with mtDNA depletion and multiple deletions limited to skeletal muscle (40) .
SSBP1 is a small protein, and much of its surface is involved in binding interactions with DNA, itself, and other replisome pro teins. The pulldown experiments in fibroblasts failed to reveal a defect in ssDNA binding, also for the p.G40V, which was pre dicted to disrupt this interaction in silico. This apparent contra diction may be explained by the fact that the pulldown experiment is not quantitative and cannot measure the dynamic of SSBP1ssDNA interaction. Conversely, the crosslinking experiment showed that p.R107Q hampers SSBP1 oligomerization, as predicted in silico for this mutation and its neighboring p.E111Q. Although p.N62D is predicted to be neutral, in vivo studies support it as a pathogenic mutation and its spatial proximity to p.R107Q suggests that the 2 mutations share the same mechanism. The recessive p.I132V was not predicted to be deleterious; however, its destabilizing poten tial, evidenced by lower thermostability, reduction of mutant SSBP1 oligomers, complementation studies in fibroblasts, and persistence of optic nerve atrophy in MO+p.I132V zebrafish, all argue in favor of its pathogenic potential.
Despite all mutant fibroblasts being characterized by a decreased mtDNA amount, only p.R107Q cells presented a reduced TFAM level and replisome proteins, according to its most severe effect on mtDNA replication. Considering that TFAM sta bilizes mtDNA by packing a single mitogenome into nucleoids (41, 42) , we would have rather expected that all mutants displayed a similar trend of reduced TFAM levels. Furthermore, we also observed a gradual worsening of mitochondrial energetic func tions based on the different mutations: no energetic alteration on p.I132V, a partial respiratory defect driven by CI reduction in p.G40V, and a very severe energetic deficit in p.R107Q. We can speculate either that this latter mutation severely affects the sta bility of the replication proteins and consequently affects bio energetic efficiency, or that p.G40V and p.I132V cells may have particularly efficient compensatory activation of mitochondrial biogenesis. Our results support this last hypothesis. Indeed, we found that p.G40V fibroblasts presented an increase of mitochon drial mass, a mechanism observed also in other mitochondrial dis eases, such as LHON (43) . Remarkably, a mechanism of increased transcription efficiency in association with mtDNA depletion was already observed in the livers of the Mpv17 KO mouse model (44) . Thus, it is not surprising that these mutant cells had milder or no respiratory defect, also considering that fibroblasts are not the tar get tissue of the pathology and may display only a very mild ener which may also reflect on phenotype expressivity. Nuclear back ground may obviously play a role, as well as mtDNA haplotype. Our complete mtDNA sequence only revealed an insertion affect ing the OH region in the younger proband with severe nephrop athy. This could affect mtDNA replication efficiency, potentially worsening the defect due to the SSBP1 mutation. Specific experi ments should be designed to confirm this hypothesis.
We documented causal association of SSBP1 mutations with the disease, demonstrating, both in vivo and in vitro, that all patients' missense SSBP1 mutations are pathogenic. First, sup pression of ssbp1 transcript in zebrafish induced reduction of optic nerve chiasm size and depletion of mitochondria numbers, possi bly also affecting kidney function. The optic nerve phenotype, the constant clinical feature in all patients, was fully rescued by WT or by the common polymorphism p.L75P mRNA, but not by mutant SSBP1 mRNA, confirming their deleteriousness. These experi ments clearly support loss of function for all dominant mutations, whereas the recessive mutation p.I132V, improving the optic nerve chiasm size less effectively as compared with WT, revealed its pos sible hypomorphic nature, which results in a disease outcome only when in homozygous state.
Second, cellular and in vitro studies clearly documented that all SSBP1 mutations hamper mtDNA replication, as was also evi dent by mtDNA copy number assessment in patients' tissues, including skeletal muscle, kidney, and blood. In fact, both the depletion/repopulation experiment after EtBr in mutant fibro blasts and the in vitro synthesis experiment confirmed that SSBP1 mutations cause reduced efficiency of mtDNA replication. Indeed, the in vitro assay showed that, even though the mutants could sup port fulllength DNA synthesis, there was a delay as compared with the reactions with WT SSBP1, indicating either lower affinity to the DNA or to the POLγ holoenzyme. Regardless of the reason, the mutants seemed to have lost some of their stimulatory effect, atmosphere of 5% CO 2 at 37°C. The mtDNA depletion/repopulation experiment was performed as described (43) . Briefly, cells were grown in glucose medium supplemented 0.05 mg/ml uridine and 50 ng/ml EtBr to induce mtDNA depletion. After 7 days, EtBr was removed from the medium and cells were propagated until the 15th day.
mtDNA content and quantification of deletions and 7S DNA. Quan tification of mtDNA copy number relative to nDNA was performed for fibroblasts, and muscle, kidney, and blood tissues, as described (54) .
Quantification of mtDNA deletion and 7S DNA was performed on fibroblasts and muscle, kidney, urine, and blood tissues. Briefly, the absolute quantification of mitochondrial genome deletions was based on duplex amplification in droplet digital PCR (ddPCR) with specific probes in MT-ND4 (major arc) and MT-ND1 (control region) adapted from published qPCR methods (55) and expressed as ratio ND4/ND1.
The quantification of 7S DNA was performed as previously described (51) and adapted to ddPCR (BioRad). The 7S DNA was expressed as ratio -1 (mean ± SD) of mtDNA+7S DNA over mtDNA using the primer pairs (a + b1) and (a + b2), respectively, where b1 is inside the 7S region, amplifying both mtDNA and 7S DNA, and b2 is outside, amplifying only mtDNA.
Oligomerization assay. SSBP1 oligomerization was carried out as described (56) . Briefly, 10 μg of mitochondria isolated from controls and patients' primary fibroblasts, as described (57), were treated or not with crosslinking agent (GA) at a final concentration of 0.1%. The reaction was quenched after 10 minutes with 100 × 10 -3 mol/L PBS/ glycine. Monomers or multimers were detected by SDS-PAGE with antiSSBP1 antibody. Densitometric analysis was carried out using ImageJ software (NIH) and was expressed as crosslinked oligomers to monomers ratio.
Pull-down assay. Pulldown assay was carried out as described (58, 59) with some modifications. Briefly, 10 μg of isolated mitochon dria were solubilized with 1% dodecylmaltoside (DDM) in binding buffer (20 mM HEPES pH 7.4, 50 × 10 -3 mol/L NaCl, 10 × 10 -3 mol/L MgCl2, 10 -3 mol/L CaCl2, 8 × 10 -3 mol/L DTT, 0.1 mg/ml BSA, 10% glycerol, 0.02% Tween 20, 1× protease inhibitor cocktail) for 30 min utes on ice; 20 μg of biotinylated ssDNA (biotin5′GGACTATTTAT TCAATATATTTAAGAACTAATTCCAGCTGAGCGCCGG) (60) was added and incubated on a wheel shaker for 30 minutes at room temperature. To each reaction, 50 μL of streptavidinagarose beads (SigmaAldrich) was added and incubated for 30 minutes at room temperature. Beads were pelleted at 600 g for 1 minute, and superna tants were collected and precipitated as described below, while pellets were washed 10 times with binding buffer and finally resuspended in 2× Laemmli buffer. Supernatants were precipitated adding 1 volume of 20% trichloroacetic acid (TCA), washed with cold acetone, airdried, and resuspended in 1× Laemmli buffer. Pulled down and supernatant fractions were analyzed by immunoblotting using antiSSBP1, anti VDAC1, antiHSP60, and antiETHE1 antibodies.
Expression and purification of recombinant proteins. Recombinant baculoviruses encoding POLγB and POLγA were expressed in Sf9 insect cells. These recombinant proteins lacked the Nterminal mito chondrial targeting sequence and carried a carboxyterminal 6′ His tag. The proteins were purified over HIS-Select Nickel Affinity Gel (SigmaAldrich) and HiTrap Heparin HP (GE Healthcare), followed by HiTrap SP HP or HiTrap Q HP columns (GE Healthcare), depend ing on the net electrical charge of the protein. SSBP1 lacking the mitochondrial targeting sequence/MTS (aa 1-16) and containing an getic defect, as previously reported (45, 46) . The SSBP1associated disease, in fact, displayed a clear tissue specificity in patients with an inconstant clinical expression in kidney, for example. Tissuespecific sensitivity to little variations in mtDNA depletion and compensatory response may determine clinical expression. In the same line, the failure to detect a clear mtDNA depletion in 2 dpf zebrafish embryos might just be due to the early stage at which this experiment was done and, again, to the tissuespecific reduc tion of the mtDNA copy number. SSBP1 is required for efficient initiation and elongation of mtDNA replication (47, 48) . A majority of all mtDNA replication events are prematurely terminated at the end of the Dloop, form ing 7S DNA. The relative levels of abortive mtDNA replication appear to be a regulated event. When more mtDNA is required, 7S DNA synthesis is reduced in favor of complete mtDNA replication (49, 50) . The drop in 7S DNA levels associated with mutations in SSBP1 is therefore most likely a compensatory effect. Even if all 3 tested mutations (p.G40V, p.R107Q, and p.I132V) negatively regulate mitochondrial genome stability, only dominant muta tions induce a severe reduction of 7S abundance. The milder reduction of 7S DNA associated with p.I132V may be compatible with its hypomorphic nature. Alterations of 7S DNA levels have also been observed in other mitochondrial disorders caused by impaired mtDNA replication (51) (52) (53) .
In conclusion, we add SSBP1 to the list of genes implicated in mtDNA maintenance human diseases. Our current findings will open many different avenues of further investigation, ultimately contributing to a better understanding of mtDNA replication, enlarging the landscape of phenotypic expression of mitochondrial diseases in humans.
Methods
Cells and culture conditions. Skin fibroblasts were derived from 7 healthy donors, 2 related patients with the p.R107Q mutation, 1 patient with the p.G40V mutation, and 1 patient with the p.I132V mutation. Fibroblasts were grown in DMEM medium supplemented with 10% FBS (FBS, Gibco, Life Technologies), 2 × 10 3 mol/L l-glutamine, 100 U/ml pen icillin, and 100 μg/ml streptomycin in an incubator with a humidified Nterminal 6′ Histag was expressed in E. coli cells and purified over HIS-Select Nickel Affinity Gel (SigmaAldrich) and HiTrap Heparin HP (GE Healthcare), followed by HiTrap SP. Patient point mutations were introduced using the QuikChange Lightning SiteDirected Muta genesis Kit (Agilent Technologies) and verified by sequencing before being expressed and purified as for WT SSBP1.
Second-strand synthesis assay. A 32Plabelled 50 nt long oligo nucleotide (5′GTGGCACTTTTCGGGGAAATGTGCGCGGAAC CCCTATTTGTTTATTTTTC-3′) was annealed to singlestranded pBluescript SK II (-). DNA synthesis assays were performed using a 10 fmol template, 200 fmol of POLγ holoenzyme, and 500 fmol (as tetramer) of WT or mutant SSBP1 in 25 × 10 -3 mol/L TrisHCl (pH 7.8), 10 -3 mol/L TCEP, 10 × 10 3 mol/L MgCl 2 , 0.1 mg/ml BSA, and 10 μM (each) dNTPs. Reactions were incubated at 37°C for the indicated times and stopped by the addition of 6 μl stop buffer (90 mM EDTA, 6% SDS, 30% glycerol, 0.25% bromophenol blue, and 0.25% xylene cyanol). Samples were separated on a 0.8% agarose gel and visualized by autoradiography.
Additional information. WES and mtDNA sequencing methods appear in Supplemental Methods. Genome data were deposited at the European Genomephenome Archive (EGA), which is hosted at the European Bioinformatics Institute (EBI) and the Centre for Genomic Regulation (CRG) (EGAS00001003850 and EGAS00001004003). Additionally, standard methods for fluorescence microscopy, OCR, Western blot, assessment of OXPHOS complexes and respiratory supercomplexes assembly, functional SSBP1 complementation, and all methods related to zebrafish experiments are detailed in the Sup plemental Methods.
Study approval. The local ethical committee at each center approved the study as follows: University of Bologna's Comitato Etico di Area Vasta Emilia Centro della Regione EmiliaRomagna (CE-AVEC) 211/2018/SPER/AUSLBO for families 1, 3, and 4; Duke University's Health System Institutional Review Board for Clini cal Investigators (DUHS IRB, FWA #00009025) protocol #32301: Genomic Study of Medical, Developmental, or Congenital Problems of Unknown Etiology, for family 2; and the Ethical Committee of the University of Innsbruck (Ethikkommission der Medizinischen Univer sität Innsbruk AN2014-0090 335/4.7) for family 5. All patients and healthy donors or their parents or guardians gave informed consent.
Statistics. GraphPad Prism for Windows (GraphPad Software) was used for statistical analyses. For patient tissues and fibroblast experi ments, comparison of 2 groups used unpaired Student's 2tailed t test and comparisons among multiple groups used 1way or 2way ANOVA with Tukey's or Dunnett's multiple comparisons tests. For zebra fish experiments, unpaired Student's 2tailed t test and ANOVA with
